WO2010114215A3 - 캠포를 유효성분으로 포함하는 비만, 이상지방혈증, 지방간 또는 인슐린 저항성 증후군의 예방 또는 치료용 조성물 - Google Patents

캠포를 유효성분으로 포함하는 비만, 이상지방혈증, 지방간 또는 인슐린 저항성 증후군의 예방 또는 치료용 조성물 Download PDF

Info

Publication number
WO2010114215A3
WO2010114215A3 PCT/KR2009/007904 KR2009007904W WO2010114215A3 WO 2010114215 A3 WO2010114215 A3 WO 2010114215A3 KR 2009007904 W KR2009007904 W KR 2009007904W WO 2010114215 A3 WO2010114215 A3 WO 2010114215A3
Authority
WO
WIPO (PCT)
Prior art keywords
composition
insulin resistance
camphor
preventing
active ingredient
Prior art date
Application number
PCT/KR2009/007904
Other languages
English (en)
French (fr)
Other versions
WO2010114215A2 (ko
Inventor
박태선
Original Assignee
연세대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 연세대학교 산학협력단 filed Critical 연세대학교 산학협력단
Publication of WO2010114215A2 publication Critical patent/WO2010114215A2/ko
Publication of WO2010114215A3 publication Critical patent/WO2010114215A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 캠포를 유효성분으로 포함하는 비만, 이상지방혈증, 지방간 또는 인슐린 저항성 증후군의 예방 또는 치료용 조성물에 관한 것이다. 본 발명의 캠포를 유효성분으로 포함하는 조성물은 지방세포 분화의 억제, 체지방량의 감소, 내장 지방량의 감소, 총콜레스테롤 농도의 감소, 혈장 중성지방 및 간조직 중성지방의 감소를 초래하여, 궁극적으로 비만, 고지혈증 또는 지방간의 예방 또는 치료 활성을 나타낸다. 또한, 본 발명의 조성물은 공복시 혈당 및 혈중 인슐린 농도의 유의한 감소를 초래하여 인슐린 저항성을 개선하는 효과 및 이와 밀접하게 관련된 대사질환을 개선하는 효능도 발휘한다. 또한, 본 발명의 조성물은 내장지방 조직에서 지방조직의 생성에 중추적 역할을 하는 핵전사 인자(C/EBPα와 PPARγ2) 또는 이의 타겟 유전자(aP2)의 발현을 유의적으로 감소시켜 내장 지방량 억제 효과를 가지고, 염증을 활성화시키는 사이토카인(TNF-α 또는 IL-6)의 발현을 유의적으로 감소시켜 내장지방조직에서 비만으로 인해 유도된 만성적 염증활성화의 개선 효과를 나타내며, 생체내 열발생을 조절하는 UCPs(UCP1 또는 UCP3) 유전자 발현을 증가시킴으로써, 내장지방조직에서 비만으로 인해 유도된 열 발생 저해현상의 개선 효과를 나
PCT/KR2009/007904 2009-04-01 2009-12-29 캠포를 유효성분으로 포함하는 비만, 이상지방혈증, 지방간 또는 인슐린 저항성 증후군의 예방 또는 치료용 조성물 WO2010114215A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020090028030A KR101032313B1 (ko) 2009-04-01 2009-04-01 캠포를 유효성분으로 포함하는 비만, 이상지방혈증, 지방간 또는 인슐린 저항성 증후군의 예방 또는 치료용 조성물
KR10-2009-0028030 2009-04-01

Publications (2)

Publication Number Publication Date
WO2010114215A2 WO2010114215A2 (ko) 2010-10-07
WO2010114215A3 true WO2010114215A3 (ko) 2010-11-25

Family

ID=42828792

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/007904 WO2010114215A2 (ko) 2009-04-01 2009-12-29 캠포를 유효성분으로 포함하는 비만, 이상지방혈증, 지방간 또는 인슐린 저항성 증후군의 예방 또는 치료용 조성물

Country Status (2)

Country Link
KR (1) KR101032313B1 (ko)
WO (1) WO2010114215A2 (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101445966B1 (ko) * 2013-03-18 2014-10-01 동의대학교 산학협력단 백두구 추출물을 포함하는 항비만 조성물
KR101539289B1 (ko) * 2013-08-16 2015-07-24 한국국제대학교 산학협력단 개똥쑥 추출물을 함유하는 지방간 또는 비만의 예방 또는 치료용 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100444400B1 (ko) * 2003-12-30 2004-08-16 전영완 기능성 세정조성물과 이를 함유한 천연 아로마 기능성 비누
JP2004346042A (ja) * 2003-05-23 2004-12-09 Sekisui Chem Co Ltd 貼付剤
KR20050081631A (ko) * 2004-02-16 2005-08-19 대한민국 (소관: 제주대학교) 녹나무 추출물을 함유하는 염증성 질환의 예방 및 치료용조성물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004346042A (ja) * 2003-05-23 2004-12-09 Sekisui Chem Co Ltd 貼付剤
KR100444400B1 (ko) * 2003-12-30 2004-08-16 전영완 기능성 세정조성물과 이를 함유한 천연 아로마 기능성 비누
KR20050081631A (ko) * 2004-02-16 2005-08-19 대한민국 (소관: 제주대학교) 녹나무 추출물을 함유하는 염증성 질환의 예방 및 치료용조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GO BYOUNG-SEOB ET AL.: "Effect of Cinnamomum camphora Leaf Fractions on Insulin Action in 3T3-L1 adipocytes", JOURNAL OF THE KOREAN SOCIETY OF FOOD SCIENCE AND NUTRITION, vol. 34, no. 9, 2005, pages 1336 - 1343, XP053026376 *

Also Published As

Publication number Publication date
KR20100109664A (ko) 2010-10-11
KR101032313B1 (ko) 2011-05-06
WO2010114215A2 (ko) 2010-10-07

Similar Documents

Publication Publication Date Title
WO2010107177A2 (ko) 캠펜을 유효성분으로 포함하는 비만, 이상지방혈증, 지방간 또는 인슐린 저항성 증후군의 예방 또는 치료용 조성물
Zeng et al. Naringenin as a potential immunomodulator in therapeutics
Santangelo et al. Polyphenols, intracellular signalling and inflammation
Ghosh et al. Curcumin ameliorates renal failure in 5/6 nephrectomized rats: role of inflammation
Yu et al. Fibroblast growth factor 21 (FGF21) ameliorates collagen-induced arthritis through modulating oxidative stress and suppressing nuclear factor-kappa B pathway
Gan et al. Celastrol attenuates bone erosion in collagen-Induced arthritis mice and inhibits osteoclast differentiation and function in RANKL-induced RAW264. 7
JP2013527177A5 (ko)
Song et al. Salidroside attenuates acute lung injury via inhibition of inflammatory cytokine production
Huang et al. Hyperin attenuates inflammation by activating PPAR-γ in mice with acute liver injury (ALI) and LPS-induced RAW264. 7 cells
Li et al. Arctiin protects against cardiac hypertrophy through inhibiting MAPKs and AKT signaling pathways
Niu et al. Protective effects of scoparone against lipopolysaccharide-induced acute lung injury
Ding et al. Epigallocatechin gallate attenuated non-alcoholic steatohepatitis induced by methionine-and choline-deficient diet
Jia et al. Fuzheng Huayu recipe prevents nutritional fibrosing steatohepatitis in mice
Ying et al. Pentamethylquercetin reduces fat deposition via Sirt1-mediated pathways in male obese mice induced by a high fat diet
Liang et al. Inhibition of RIPK1/RIPK3 ameliorates osteoclastogenesis through regulating NLRP3-dependent NF-κB and MAPKs signaling pathways
Liang et al. Naringin regulates cholesterol homeostasis and inhibits inflammation via modulating NF-κB and ERK signaling pathways in vitro
Bignold et al. Effects of cytokine signaling inhibition on inflammation-driven tissue remodeling
Zhang et al. Potent effects of dioscin against thioacetamide-induced liver fibrosis through attenuating oxidative stress in turn inhibiting inflammation, TGF-β/Smad and MAPK signaling pathways
WO2010114215A2 (ko) 캠포를 유효성분으로 포함하는 비만, 이상지방혈증, 지방간 또는 인슐린 저항성 증후군의 예방 또는 치료용 조성물
Yang et al. Esculin ameliorates obesity-induced insulin resistance by improving adipose tissue remodeling and activating the IRS1/PI3K/AKT/GLUT4 pathway
WO2016048005A3 (ko) 신규한 펜타디에노일 피페리딘 유도체 및 그의 용도
Jagannath et al. Novel and experimental therapies in chronic pancreatitis
Ravindranath et al. Green tea catechins suppress NF-κB-mediated inflammatory responses: relevance to nutritional management of inflammation
Sari et al. Zerumbone prevents pressure overload-induced left ventricular systolic dysfunction by inhibiting cardiac hypertrophy and fibrosis
Balkrishna et al. Divya-WeightGo combined with moderate aerobic exercise remediates adiposopathy, insulin resistance, serum biomarkers, and hepatic lipid accumulation in high-fat diet-induced obese mice

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09842752

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09842752

Country of ref document: EP

Kind code of ref document: A2